Immune modulation and increased neurotrophic factor production in multiple sclerosis patients treated with testosterone
Open Access
- 31 July 2008
- journal article
- clinical trial
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 5 (1) , 32
- https://doi.org/10.1186/1742-2094-5-32
Abstract
Background: Multiple sclerosis is a chronic inflammatory disease of the central nervous system with a pronounced neurodegenerative component. It has been suggested that novel treatment options are needed that target both aspects of the disease. Evidence from basic and clinical studies suggests that testosterone has an immunomodulatory as well as a potential neuroprotective effect that could be beneficial in MS.Methods: Ten male MS patients were treated with 10 g of gel containing 100 mg of testosterone in a cross-over design (6 month observation period followed by 12 months of treatment). Blood samples were obtained at three-month intervals during the observation and the treatment period. Isolated blood peripheral mononuclear cells (PBMCs) were used to examine lymphocyte subpopulation composition by flow cytometry andex vivoprotein production of cytokines (IL-2, IFNγ, TNFα, IL-17, IL-10, IL-12p40, TGFβ1) and growth factors (brain-derived neurotrophic factor BDNF, platelet-derived growth factor PDGF-BB, nerve growth factor NGF, and ciliary neurotrophic factor CNTF). Delayed type hypersensitivity (DTH) skin recall tests were obtained before and during treatment as anin vivofunctional immune measure.Results: Testosterone treatment significantly reduced DTH recall responses and induced a shift in peripheral lymphocyte composition by decreasing CD4+ T cell percentage and increasing NK cells. In addition, PBMC production of IL-2 was significantly decreased while TGFβ1 production was increased. Furthermore, PBMCs obtained during the treatment period produced significantly more BDNF and PDGF-BB.Conclusion: These results are consistent with an immunomodulatory effect of testosterone treatment in MS. In addition, increased production of BDNF and PDGF-BB suggests a potential neuroprotective effect.Trial Registration: NCT00405353http://www.clinicaltrials.govKeywords
This publication has 41 references indexed in Scilit:
- Toward the development of rational therapies in multiple sclerosis: what is on the horizon?Annals of Neurology, 2007
- Multiple sclerosis: a complicated picture of autoimmunityNature Immunology, 2007
- Neurotrophic and neuroprotective actions of estrogen: Basic mechanisms and clinical implicationsSteroids, 2007
- Regulatory CD56brightnatural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosisProceedings of the National Academy of Sciences, 2006
- Neurotrophic Factors and Clinical Recovery in Relapsing‐Remitting Multiple SclerosisScandinavian Journal of Immunology, 2005
- Platelet-derived growth factor-BB pretreatment attenuates excitotoxic death in cultured hippocampal neuronsNeurobiology of Disease, 2005
- IMMUNOLOGY OF MULTIPLE SCLEROSISAnnual Review of Immunology, 2005
- Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approachesNature Neuroscience, 2002
- Activated Human T Cells, B Cells, and Monocytes Produce Brain-derived Neurotrophic Factor In Vitro and in Inflammatory Brain Lesions: A Neuroprotective Role of Inflammation?The Journal of Experimental Medicine, 1999
- Sex Hormone Modulation of Neural Development in VitroHormones and Behavior, 1994